Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms
- 20 May 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cellular & Molecular Immunology
- Vol. 17 (6), 576-586
- https://doi.org/10.1038/s41423-020-0464-1
Abstract
Gene engineering and combinatorial approaches with other cancer immunotherapy agents may confer capabilities enabling full tumor rejection by adoptive T cell therapy (ACT). The provision of proper costimulatory receptor activity and cytokine stimuli, along with the repression of inhibitory mechanisms, will conceivably make the most of these treatment strategies. In this sense, T cells can be genetically manipulated to become refractory to suppressive mechanisms and exhaustion, last longer and differentiate into memory T cells while endowed with the ability to traffic to malignant tissues. Their antitumor effects can be dramatically augmented with permanent or transient gene transfer maneuvers to express or delete/repress genes. A combination of such interventions seeks the creation of the ultimate bionic T cell, perfected to seek and destroy cancer cells upon systemic or local intratumor delivery.Keywords
Funding Information
- Ministerio de Economía y Competitividad (SAF 2017-83267-C2-1R)
- Fundación Científica Asociación Española Contra el Cáncer
This publication has 154 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell TherapyPLOS ONE, 2013
- Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody ReceptorClinical Cancer Research, 2011
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer ImmunotherapyClinical Cancer Research, 2011
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient ColitisMolecular Therapy, 2011
- Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironmentsProceedings of the National Academy of Sciences of the United States of America, 2010
- Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer CellsClinical Cancer Research, 2008
- TGF-β: A Master of All T Cell TradesCell, 2008
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1The New England Journal of Medicine, 2008
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006